{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-21-000175","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2021-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.448630+00:00","generated_at":"2026-06-29T09:41:23.367109+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lilly restructures leadership; Zulueta retiring, Yuffa to lead International, new Neuroscience & Immunology units","bullets":["Alfonso Zulueta, President of Lilly International, to retire effective Dec 26, 2021; succeeded by Ilya Yuffa.","Lilly Bio-Medicines splits into two units: Lilly Neuroscience (led by Anne White) and Lilly Immunology (led by Patrik Jonsson).","Jake Van Naarden promoted to CEO of Loxo Oncology at Lilly and President of Lilly Oncology, joins executive committee.","Donanemab (Alzheimer's) BLA submission planned under accelerated approval pathway; tirzepatide (type 2 diabetes) potential launch cited.","Changes effective Sept 5, 2021; CEO David Ricks cites focus on late-stage pipeline and breakthrough medicines."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-21-000175","json":"https://secwatch.observer/filing/0000059478-21-000175.json","markdown":"https://secwatch.observer/filing/0000059478-21-000175.md","text":"https://secwatch.observer/filing/0000059478-21-000175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000175/0000059478-21-000175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000175/lly-20210811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T09:41:23.367109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e36af8fe59","claim":"Alfonso Zulueta departed as Senior Vice President and President, Lilly International at ELI LILLY & Co.","evidence_excerpt":"On August 11, 2021, Alfonso Zulueta, Senior Vice President and President, Lilly International, of Eli Lilly and Company (the “Company”) notified the Board of Directors of the Company of his intent to retire from his position with the Company effective as of December 26, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000175/0000059478-21-000175-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Senior Vice President and President, Lilly International"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}